List view / Grid view
Scaling up cell therapy is no easy feat. PluriCDMO's Andy Lewin reveals the critical factors for success and how they are helping companies bring life-saving therapies to market.
Professor Jens Christian Schwamborn is advancing personalised medicine for Parkinson’s disease using patient-specific brain organoids, offering new hope for more effective and targeted treatments.
19 February 2025 | By
Discover the transformative potential of iPSC-based therapies in regenerative medicine, alongside their challenges including scalability, safety and targeted delivery.
The human body has an incredible ability to repair itself, both from acute trauma and chronic damage that accumulates as we age. Here, Cameron Lee, Principal Scientist at Tune Therapeutics, reveals the potential of harnessing the body’s natural regenerative capabilities with epigenetic control of stem cells.
The self-assembly of human liver tissues in low Earth orbit could improve their differentiation and functionality.
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
Human brain organoids are complex in vitro tools derived from stem cells, designed to model the molecular basis of neurodevelopment and the pathogenesis of neurological disorders. By mimicking the function of the human brain, in both health and disease, their application in drug discovery holds significant potential for identifying new…
The hiPSC-derived skeletal muscle model is the first to uncover the biological mechanisms underlying loss of mobility.
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
Induced NPCs facilitate the creation of patient-specific organoid models and improve identification of nephron targeted drugs.
Injections of cardiac spheroids into primate ventricles improved left ventricular ejection after four weeks.
Researchers have improved the method of regenerating heart muscle after a heart attack using a combination of iPSC-derived cells.
CRISPR-DREAM tool used to activate insufficiently expressed genes and convert skin cells to induced pluripotent stem cells (iPSCs).
Japanese researchers successfully engineered iPSCs to secrete a modified enzyme, mNAGA, and restored enzyme activity in vitro and in a mouse model, opening new avenues for regenerative medicine for conditions such as Fabry Disease.
